Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
11/2003
11/26/2003CN1458841A Use of matrix metalloprotease ihibitors for treatment of cancer
11/26/2003CN1458282A Preparing method for producing high level immunity induced by nucleic molecule and using method
11/26/2003CN1458280A Two artificial synthetic PRRS virus multiple opitope tandem pucleotide sequences and their use
11/25/2003US6653467 Antisense oligonucleotide selected from RNA or DNA, of given sequence, where each uracil is replaced with thymine; used to correct the shift of the reading frame; dystrophin
11/25/2003US6653466 Active principle comprises antisense oligonucleotide consisting of a 20 to 50-nucleotide sequence against exon 19 of dystrophin pre-mRNA
11/25/2003US6653465 Spliced gene of KSHV / HHV8, its promoter and monoclonal antibodies specific for LANA2
11/25/2003US6653448 Wnt-7B-like polypeptides and nucleic acids encoding same
11/25/2003US6653445 Chemotactic cytokine V (CCV); isolated protein of given sequence; use in diagnostics and as anti-viral or anti-tumor agent
11/25/2003US6653382 Ethylene-unsaturated carboxylic acid copolymer; ionomers; resilience, melt processability
11/25/2003US6653292 Stimulating Th1 pattern of immune activation, cytokine production, NK lytic activity and B cell proliferation; modulating with nucleic acid sequences containing unmethylated CpG dinucleotides
11/25/2003US6653291 Composition and method for production of transformed cells
11/25/2003US6653278 Selenium-containing pro-drugs for cancer therapy
11/25/2003US6653134 Obtaining a bone marrow sample from a human, isolating stromal cells, and administering to the central nervous system of the patient; treating a genetic disease, a tumor, trauma and stroke
11/25/2003US6653133 Antisense modulation of Fas mediated signaling
11/25/2003US6653128 Especially for rickettsial pathogen selected from the group consisting of Rickettsia spp., Ehrlichia spp., Anaplasma spp., and Cowdria
11/25/2003US6653125 Synthetic hepatitis C genes
11/25/2003US6653118 Deoxyribonuclease, gene encoding same and use thereof
11/25/2003US6653100 hKCa3/KCNN3 small conductance calcium activated potassium channel: A diagnostic marker and therapeutic target
11/25/2003US6653098 Transforming cell with an expression vector comprising an isolated polynucleotide; solubilizing the inclusion bodies; refolding and purifying; urea, dithiothreitol and cysteine; angiogenesis inhibitors; anticarcinogenic agents
11/25/2003US6653072 Improving expression of a protein encoded by DNA substrate by assembling oligonucleotides into recombinant nucleic acids and using it to transform cells; recursive sequence recombination
11/25/2003US6652873 Compositions and methods for enhancing receptor-mediated cellular internalization
11/25/2003US6652860 Peptide, apoEp 1.B, compositions and uses thereof
11/25/2003US6652858 Administering an OX-2 protein or a nucleic acid encoding it to preventing graft rejection, fetal loss, autoimmune disease, and allergies; immunosuppressants; gene therapy
11/25/2003US6652851 Cloning and recombinant production of polistinae venom enzymes, such as phospholipase and hyaluronidase, and immunological therapies based thereon
11/25/2003US6652850 Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
11/25/2003US6652849 A vector expressed in obligate anaerobes for the production of an enzyme capable of converting a non toxic prodrug to a toxic chemotherapeutic agent.
11/25/2003CA2194166C Multi-stage cascase boosting vaccine
11/25/2003CA2119145C Ferrite particles and therapeutic and diagnostic uses therefore
11/21/2003CA2428112A1 Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia
11/20/2003WO2003096017A1 Methods and compositions for inducing an immune response
11/20/2003WO2003095971A2 Posh nucleic acids, polypeptides and related methods
11/20/2003WO2003095678A1 Ldl receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions
11/20/2003WO2003095656A1 Recombinant fowlpox virus
11/20/2003WO2003095652A2 Expression constructs for producing double-stranded (ds) rna and the use thereof
11/20/2003WO2003095647A2 CHIMERIC snRNA MOLECULES CARRYING ANTISENSE SEQUENCES AGAINST THE SPLICE JUNCTIONS OF THE DYSTROPHIN GENE AND THEIR THERAPEUTIC APPLICATIONS
11/20/2003WO2003095613A2 Nucleic acids, polypeptides, and methods for modulating apoptosis
11/20/2003WO2003095485A2 Krib polynucleotides and polypeptides and uses thereof in the treatment of metabolic disorders
11/20/2003WO2003095480A2 Brachyspira hyodysenteriae vaccine
11/20/2003WO2003094974A1 Complexes for the delivery of biologically-active material to cells
11/20/2003WO2003094971A1 Cationic lipids for intracellular delivery of bioactive substances
11/20/2003WO2003094963A2 Methylated immunostimulatory oligonucleotides and methods of using the same
11/20/2003WO2003094862A2 tRNA SYNTHASE: MODULATORS OF ANGIOGENESIS
11/20/2003WO2003094859A2 Epha2 monoclonal antibodies and methods of use thereof
11/20/2003WO2003094846A2 Intrathecal and intratumoral superantigens to treat malignant disease
11/20/2003WO2003094836A2 Methods and products for enhancing immune responses using imidazoquinoline compounds
11/20/2003WO2003094829A2 Pathogen vaccines and methods for using the same
11/20/2003WO2003094828A2 Cancer vaccines and methods of using the same
11/20/2003WO2003094697A2 Methods and compositions for correction of cardiac conduction disturbances
11/20/2003WO2003094617A2 Use of vegf for treating bone defects
11/20/2003WO2003084479A3 Large scale methods of producing adenovirus and adenovirus seed stocks
11/20/2003WO2003073995A3 Dna vaccine against proliferating endothelial cells and methods of use thereof.
11/20/2003WO2003072016A3 Pharmaceutical compositions in particulate form
11/20/2003WO2003055915A3 Human netrin receptor and uses thereof
11/20/2003WO2003054165A3 Genetic markers and methods for the diagnosis, treatment and prevention of tumor metastasis
11/20/2003WO2003054012A3 Leptin proteins
11/20/2003WO2003050504A3 Methods and compositions to treat cardiovascular disease usin g 1419, 58765 and 2201
11/20/2003WO2003046124A3 Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
11/20/2003WO2003044172A3 Composition comprising and method of using angiopoietin-like protein 3 angptl3
11/20/2003WO2003040399A3 Therapeutic methods for nucleic acid delivery vehicles
11/20/2003WO2003040327A3 Novel human proteins, polynucleotides encoding them and methods of using the same
11/20/2003WO2003039458A3 TREATMENT OF HUMAN CANCER WITH ADENOVIRAL VECTOR EXPRESSING TNF-α
11/20/2003WO2003022998A3 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
11/20/2003WO2003020931A3 Sirna knockout assay method and constructs
11/20/2003WO2003019136A3 Methods for inhibiting angiogenesis
11/20/2003WO2003012093A3 Regulator of calcineurin
11/20/2003WO2003012050A3 Mitochondrial genome replenishment
11/20/2003WO2003008444A3 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
11/20/2003WO2003006616A3 Pseudotyped adeno-associated viruses and uses thereof
11/20/2003WO2003004088A3 Method of administration of a gene of interest to the heart and vasculature
11/20/2003WO2003000021A3 Pancam nucleic acids and polypeptides
11/20/2003WO2002099116A3 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
11/20/2003WO2002095011A3 Inactivation of genes of the mep pathway
11/20/2003WO2002088181A3 Mrp8/mrp14 heterodimer, or its individual components in combination, for treating and/or preventing skin diseases, wounds and/or wound-healing disturbances
11/20/2003WO2002085287A3 Minimal adenoviral vectors for immunization
11/20/2003WO2002083736A3 G-protein coupled receptor molecules and uses thereof
11/20/2003WO2002079249A3 New polynucleotides and polypeptides of the ifn$g(a)-21 gene
11/20/2003WO2002061110A8 Nucleic acid derivatives
11/20/2003WO2002034915A3 Preferred segments of neural thread protein and methods of using the same
11/20/2003US20030217377 Oligonucleotide-directed repair or alteration of genetic information
11/20/2003US20030216559 Medical diagnosis using polypeptide; amplification, determination, calibration; monitoring immunotherapy
11/20/2003US20030216369 Administering compounds which inhibit heat shock protein 90 proteins; methods block Rb negative or deficient cells in the G2/M phase of the cell cycle and rapidly causes their destruction
11/20/2003US20030216347 Genetic material composed of a polynucleotide complexed with an amphipathic compound, a polymer or a nonviral vector is delivered to the parenchymal cell altering its endogenous properties
11/20/2003US20030216346 Gene carrier
11/20/2003US20030216344 Antisense oligonucleotide against human acetylcholinesterase (AChE) and uses thereof
11/20/2003US20030216340 Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
11/20/2003US20030216337 Composition and imaging methods for pharmacokinetic and pharmacodynamic evaluation of therapeutic delivery system
11/20/2003US20030216336 Suppression of nuclear factor-kappaB dependent processes using oligonucleotides
11/20/2003US20030216335 Treating endometriosis by contacting the subject with a nucleic acid that modulates the expression of VEGF, VEGFR1, and/or VEGFR2
11/20/2003US20030216332 Nucleic acid sequences that are shorter than wild-type dystrophin cDNA and that express mini-dystrophin peptides that function in a similar manner as wild-type dystrophin proteins; used to treat muscular distrophy
11/20/2003US20030216296 Amino acid sequences that mediate effective delivery of nucleic acids into cells and tissues, optionally using liposomes
11/20/2003US20030216290 Methods and compositions of treating and/or preventing diabetic retinopathy with pericyte apoptosis inhibitors
11/20/2003US20030216288 Methods and compositions for treating aids and HIV-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules
11/20/2003US20030216286 Methods and compositions for inhibiting angiogenesis
11/20/2003US20030215947 Methods for enhancing targeted gene alteration using oligonucleotides
11/20/2003US20030215944 Comprise nucleotide sequences which target and suppress express for nucleic acids coding receptor protein for treating cancer and psoriasis; gene expression inhibition
11/20/2003US20030215943 Antisense modulation of apolipoprotein B expression
11/20/2003US20030215921 Vascular endothelial growth factor-2
11/20/2003US20030215898 Methods for using 22045, a human cyclic nucleotide phosphodiesterase
11/20/2003US20030215879 Comprise enzymatic polypeptide for use in the treatment of inflammation; aniinflammatory agents
11/20/2003US20030215852 Novel pancortin-Pablo protein interactions and methods of use thereof
1 ... 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 ... 870